Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas

Christoph Schliemann, Teresa Hemmerle, Andrew F. Berdel, Linus Angenendt, Andrea Kerkhoff, Jan Philipp Hering, Walter Heindel, Wolfgang Hartmann, Eva Wardelmann, Sant P. Chawla, Filippo de Braud, Georg Lenz, Dario Neri, Torsten Keßler, Wolfgang E. Berdel